Close
  Indian J Med Microbiol
 

Figure 2: PD-1/PD-L1 blockade enhances tumor rejection by activating T-cells. (Left) when PD-1/PD-L1 pathway is active. Promotes survival of cancer cells through anti-apoptotic signals mediated through PD-L1 and inhibits signaling pathways that lead to activation and expansion of T-cells that recognize tumor antigens. (Right) Blocking the PD-1/PD-L1 immune checkpoint pathway by anti-PD-1 or anti-PD-L1 antibodies suppresses cancer cell survival and enhances the antitumor responses of T-cells, leading to tumor regression and rejection. PD-1: Programmed cell death protein 1

Figure 2: PD-1/PD-L1 blockade enhances tumor rejection by activating T-cells. (Left) when PD-1/PD-L1 pathway is active. Promotes survival of cancer cells through anti-apoptotic signals mediated through PD-L1 and inhibits signaling pathways that lead to activation and expansion of T-cells that recognize tumor antigens. (Right) Blocking the PD-1/PD-L1 immune checkpoint pathway by anti-PD-1 or anti-PD-L1 antibodies suppresses cancer cell survival and enhances the antitumor responses of T-cells, leading to tumor regression and rejection. PD-1: Programmed cell death protein 1